Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Organogenesis Holdings (ORGO) Capital Expenditures: 2018-2025

Historic Capital Expenditures for Organogenesis Holdings (ORGO) over the last 8 years, with Sep 2025 value amounting to $2.2 million.

  • Organogenesis Holdings' Capital Expenditures fell 13.00% to $2.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $12.9 million, marking a year-over-year increase of 28.66%. This contributed to the annual value of $10.0 million for FY2024, which is 58.82% down from last year.
  • As of Q3 2025, Organogenesis Holdings' Capital Expenditures stood at $2.2 million, which was down 38.57% from $3.6 million recorded in Q2 2025.
  • Organogenesis Holdings' Capital Expenditures' 5-year high stood at $16.7 million during Q3 2021, with a 5-year trough of $1.9 million in Q2 2024.
  • In the last 3 years, Organogenesis Holdings' Capital Expenditures had a median value of $3.4 million in 2024 and averaged $4.0 million.
  • In the last 5 years, Organogenesis Holdings' Capital Expenditures surged by 185.57% in 2021 and then tumbled by 74.93% in 2024.
  • Over the past 5 years, Organogenesis Holdings' Capital Expenditures (Quarterly) stood at $5.2 million in 2021, then skyrocketed by 103.86% to $10.7 million in 2022, then tumbled by 68.81% to $3.3 million in 2023, then rose by 1.11% to $3.4 million in 2024, then declined by 13.00% to $2.2 million in 2025.
  • Its last three reported values are $2.2 million in Q3 2025, $3.6 million for Q2 2025, and $3.6 million during Q1 2025.